Kiniksa Pharmaceuticals International, plc (KNSA) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Kiniksa Pharmaceuticals International, plc (KNSA) closed at USD 78.84 on 2026-10-14, a change of +99.9 % over the past year, with a market capitalization of USD 6.15B.

Kiniksa Pharmaceuticals International, plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Kiniksa Pharmaceuticals International, plc key figures

Previous close

USD 78.84 (2026-10-14)

1-year change

+99.9 %

Market cap

USD 6.15B

Enterprise value

USD 5.72B

P/E ratio (trailing)

79.15

P/E ratio (forward)

49.42

EPS (trailing)

1.01

EPS (forward)

1.62

PEG ratio

n/a

Price to book

9.53

Revenue growth

55.4 %

Earnings growth

30.4 %

Dividend per share (trailing)

0.00

Short ratio

6.69

Employees

366

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Kiniksa Pharmaceuticals International, plc and compare it with other stocks.